Calvisi, Diego F.

Cholangiocarcinoma 2020: the next horizon in mechanisms and management

Banales, J. M., Marin, J. J. G., Lamarca, A., Rodrigues, P. M., Khan, S. A., Roberts, L. R., Cardinale, V., Carpino, G., Andersen, J. B., Braconi, C., et al. (2020) · Nature Reviews Gastroenterology & Hepatology

Cholangiocarcinoma and Gallbladder Cancer StudiesPediatric Hepatobiliary Diseases and Treatments

Cited by 2,411

Cholangiocarcinomas can originate from hepatocytes in mice

Fan, B., Malato, Y., Calvisi, D. F., Naqvi, S., Razumilava, N., Ribback, S., Gores, G. J., Dombrowski, F., Evert, M., Chen, X., et al. (2012) · Journal of Clinical Investigation

Cholangiocarcinoma and Gallbladder Cancer StudiesPediatric Hepatobiliary Diseases and Treatments

Cited by 529

Yes-Associated Protein Up-regulates Jagged-1 and Activates the NOTCH Pathway in Human Hepatocellular Carcinoma

Tschaharganeh, D. F., Chen, X., Latzko, P., Malz, M., Gaida, M. M., Felix, K., Ladu, S., Singer, S., Pinna, F., Gretz, N., et al. (2013) · Gastroenterology

Hippo pathway signaling and YAP/TAZCancer-related molecular mechanisms research

Cited by 326

p53-Dependent Nestin Regulation Links Tumor Suppression to Cellular Plasticity in Liver Cancer

Tschaharganeh, D. F., Xue, W., Calvisi, D. F., Evert, M., Michurina, T. V., Dow, L. E., Banito, A., Katz, S. F., Kastenhuber, E. R., Weissmueller, S., et al. (2014) · Cell

Cancer-related Molecular PathwaysLiver physiology and pathology

Cited by 227

Inhibiting Glutamine-Dependent mTORC1 Activation Ameliorates Liver Cancers Driven by β-Catenin Mutations

Adebayo Michael, A. O., Ko, S., Tao, J., Moghe, A., Yang, H., Xu, M., Russell, J. O., Pradhan-Sundd, T., Liu, S., Singh, S., et al. (2019) · Cell Metabolism

PI3K/AKT/mTOR signaling in cancerWnt/β-catenin signaling in development and cancer

Cited by 155

Harnessing big ‘omics’ data and AI for drug discovery in hepatocellular carcinoma

Chen, B., Garmire, L., Calvisi, D. F., Chua, M.-S., Kelley, R. K., & Chen, X. (2020) · Nature Reviews Gastroenterology & Hepatology

Hepatocellular Carcinoma Treatment and PrognosisComputational Drug Discovery Methods

Cited by 154

Disruption of β-catenin pathway or genomic instability define two distinct categories of liver cancer in transgenic mice

Calvisi, D. F., Factor, V. M., Ladu, S., Conner, E. A., & Thorgeirsson, S. S. (2004) · Gastroenterology

Wnt/β-catenin signaling in development and cancerHepatocellular Carcinoma Treatment and Prognosis

Cited by 100

Loss of Fbxw7 synergizes with activated Akt signaling to promote c-Myc dependent cholangiocarcinogenesis

Wang, J., Wang, H., Peters, M., Ding, N., Ribback, S., Utpatel, K., Cigliano, A., Dombrowski, F., Xu, M., Chen, X., et al. (2019) · Journal of Hepatology

Cholangiocarcinoma and Gallbladder Cancer StudiesPediatric Hepatobiliary Diseases and Treatments

Cited by 87

Activation of v-Myb avian myeloblastosis viral oncogene homolog-like2 (MYBL2)-LIN9 complex contributes to human hepatocarcinogenesis and identifies a subset of hepatocellular carcinoma with mutant p53

Calvisi, D. F., Simile, M. M., Ladu, S., Frau, M., Evert, M., Tomasi, M. L., Demartis, M. I., Daino, L., Seddaiu, M. A., Brozzetti, S., et al. (2011) · Hepatology

Cancer-related Molecular PathwaysHepatocellular Carcinoma Treatment and Prognosis

Cited by 65

Mybl2 expression is under genetic control and contributes to determine a hepatocellular carcinoma susceptible phenotype

Frau, M., Ladu, S., Calvisi, D. F., Simile, M. M., Bonelli, P., Daino, L., Tomasi, M. L., Seddaiu, M. A., Feo, F., & Pascale, R. M. (2011) · Journal of Hepatology

Clusterin in disease pathologyHepatocellular Carcinoma Treatment and Prognosis

Cited by 60

TBX3 functions as a tumor suppressor downstream of activated CTNNB1 mutants during hepatocarcinogenesis

Liang, B., Zhou, Y., Qian, M., Xu, M., Wang, J., Zhang, Y., Song, X., Wang, H., Lin, S., Ren, C., et al. (2021) · Journal of Hepatology

Wnt/β-catenin signaling in development and cancerHippo pathway signaling and YAP/TAZ

Cited by 55

Overexpression of TBX3 suppresses tumorigenesis in experimental and human cholangiocarcinoma

Deng, S., Lu, X., Wang, X., Liang, B., Xu, H., Yang, D., Cui, G., Yonemura, A., Paine, H., Zhou, Y., et al. (2024) · Cell Death & Disease

Cholangiocarcinoma and Gallbladder Cancer StudiesPediatric Hepatobiliary Diseases and Treatments

Cited by 2